BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El Kassas M, Elbaz T, Elsharkawy A, Omar H, Esmat G. HCV in Egypt, prevention, treatment and key barriers to elimination. Expert Rev Anti Infect Ther. 2018;16:345-350. [PMID: 29506418 DOI: 10.1080/14787210.2018.1448709] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 El Kassas M, Abdelkader H, Medhat MA. COVID-19 in Egypt: Through crisis to adaptation; a gastroenterologist's perspective. Arab J Gastroenterol. 2020;21:207-210. [PMID: 32798187 DOI: 10.1016/j.ajg.2020.07.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Ward JW, Hinman AR. What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats. Gastroenterology. 2019;156:297-310. [PMID: 30391470 DOI: 10.1053/j.gastro.2018.10.048] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
3 El Kassas M, El Sheemy R, Alboraie M, El Badry M, Wifi MN, Youssef N, Ezzat S, Tahoon M, Abdelsalam L, Abdelhakam SM, Ali-eldin Z. Real-world results of direct-acting antivirals use for the treatment of chronic hepatitis C in old patients. Eur Geriatr Med 2019;10:295-302. [DOI: 10.1007/s41999-019-00167-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 El Kassas M, Hegazy OM, Salah EM. Effect of treating chronic hepatitis C with direct-acting antivirals on extrahepatic cutaneous manifestations. World J Hepatol 2020; 12(10): 841-849 [PMID: 33200021 DOI: 10.4254/wjh.v12.i10.841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Sakr AA, Ahmed AE, Abd El-Maksoud MDE, Gamal A, El-Garem H, Ahmed OM. Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin. Infect Genet Evol 2020;86:104606. [PMID: 33127459 DOI: 10.1016/j.meegid.2020.104606] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 El Kassas M, Salah E, Gad A, Hosny A. Improvement of sexual dysfunction in patients after treatment of hepatitis C virus using directly acting antivirals. Curr Med Res Opin 2021;37:967-72. [PMID: 33688780 DOI: 10.1080/03007995.2021.1901677] [Reference Citation Analysis]
7 Gamal-AbdelNaser A, Mohammed WS, ElHefnawi M, AbdAllah M, Elsharkawy A, Zahran FM. The oral microbiome of treated and untreated chronic HCV infection: A preliminary study. Oral Dis 2021. [PMID: 34396636 DOI: 10.1111/odi.14007] [Reference Citation Analysis]
8 El Kassas M, Alboraie M, Omar H, El Latif YA, Algaber MA, El Tahan A, El Halwagy H, Afify S, Elserafy M, Elsaeed K, Doss W. High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results. J Med Virol 2019. [PMID: 30950069 DOI: 10.1002/jmv.25478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
9 Wahb AMSE, El Kassas M, Khamis AK, Elhelbawy M, Elhelbawy N, Habieb MSE. Circulating microRNA 9-3p and serum endocan as potential biomarkers for hepatitis C virus-related hepatocellular carcinoma. World J Hepatol 2021; 13(11): 1753-1765 [PMID: 34904043 DOI: 10.4254/wjh.v13.i11.1753] [Reference Citation Analysis]
10 Esmat G, Elbaz T, Elsharkawy A, Abdullah M, El Kassas M. Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt. Expert Rev Anti Infect Ther 2020;18:637-42. [PMID: 32302245 DOI: 10.1080/14787210.2020.1758065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 El Kassas M, Alboraie M, Omran D, Salaheldin M, Wifi MN, ElBadry M, El Tahan A, Ezzat S, Moaz E, Farid AM, Omar H, Abouelkhair M, Afify S, Elsaeed K, Shazly Y, Doss W, Esmat G. An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. Expert Rev Gastroenterol Hepatol. 2018;12:1265-1272. [PMID: 29757684 DOI: 10.1080/17474124.2018.1476137] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
12 Soliman G, Elzalabany MS, Hassanein T, Miller FD. Mass screening for hepatitis B and C in Southern Upper Egypt. BMC Public Health 2019;19:1326. [PMID: 31640639 DOI: 10.1186/s12889-019-7640-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ebid AIM, Ahmed OA, Agwa SH, Abdel-Motaleb SM, Hagag RS. Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients. Int J Clin Pharm 2020;42:1207-16. [PMID: 32712884 DOI: 10.1007/s11096-020-01085-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Crespo J, Albillos A, Buti M, Calleja JL, García-Samaniego J, Hernández-Guerra M, Serrano T, Turnes J, Acín E, Berenguer J, Berenguer M, Colom J, Fernández I, Fernández Rodríguez C, Forns X, García F, Rafael Granados, Lazarus JV, Molero JM, Molina E, Pérez Escanilla F, Pineda JA, Rodríguez M, Romero M, Roncero C, Saiz de la Hoya P, Sánchez Antolín G. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). Gastroenterol Hepatol 2019;42:579-92. [PMID: 31594683 DOI: 10.1016/j.gastrohep.2019.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
15 Crespo J, Albillos A, Buti M, Calleja JL, Garcia-samaniego J, Hernández-guerra M, Serrano T, Turnes J, Acín E, Berenguer J, Berenguer M, Colom J, Fernández I, Fernández Rodríguez C, Forns X, García F, Granados R, Lazarus J, Molero JM, Molina E, Pérez Escanilla F, Pineda JA, Rodríguez M, Romero M, Roncero C, Saiz de la Hoya P, Sánchez Antolín G. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). Gastroenterología y Hepatología (English Edition) 2019;42:579-92. [DOI: 10.1016/j.gastre.2019.09.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
16 Ezzat R, Eltabbakh M, El Kassas M. Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures. World J Gastrointest Oncol 2021; 13(12): 1919-1938 [DOI: 10.4251/wjgo.v13.i12.1919] [Reference Citation Analysis]
17 Shousha HI, Said M, ElAkel W, ElShafei A, Esmat G, Waked E, Elsayed MH, Doss W, Elrazky M, Mehrez M, Hassany M, Zeyada D, Anis M, Alserafy M. Assessment of facility performance during mass treatment of chronic hepatitis C in Egypt: Enablers and obstacles. J Infect Public Health 2020;13:1322-9. [PMID: 32473817 DOI: 10.1016/j.jiph.2020.05.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
18 Medhat MA, El Kassas M. Letter regarding "High rates of 30-day mortality in patients with cirrhosis and COVID-19". J Hepatol 2020;73:1569-70. [PMID: 32574577 DOI: 10.1016/j.jhep.2020.06.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Dhiman RK, Grover GS, Premkumar M. Hepatitis C elimination: a Public Health Perspective. Curr Treat Options Gastro 2019;17:367-77. [DOI: 10.1007/s11938-019-00240-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]